What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?

AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 results for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The EPCORE DLBCL-2 study showed a statistically significant reduction in the risk of disease progression or death versus R-CHOP alone. Trial data point to clinically meaningful efficacy in a first line setting for high risk diffuse large B cell lymphoma patients. Epcoritamab plus R-CHOP is only one piece of the story for AbbVie as the oncology pipeline...